Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial.

International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings.

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study.

Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.

More Frequent than Annual Administration of COVID-19 Vaccination May Be Appropriate for Patients With Cancer.

Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC.

Management of Patients With EGFR Exon 20-Mutant Advanced Non-Small Cell Lung Cancer.

Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.

HSR25-167: Real-World Study Demonstrates Lack of Biomarker-driven Care in First-Line Treatment for Advanced/Metastatic Non-Small Cell Lung Cancer That Received Next-Generation Sequencing Testing.

Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy.

Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC.

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice.

Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking.

A novel machine learning-based cancer-specific cardiovascular disease risk score among patients with breast, colorectal, or lung cancer.